Chronic Myeloproliferative Disorders  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chronic Myeloproliferative Disorders
NCT00005846: Tipifarnib in Treating Patients With Myeloproliferative Disorders

Active, not recruiting
1/2
US
tipifarnib
Stanford University, National Cancer Institute (NCI)
Leukemia, Myelodysplastic/Myeloproliferative Neoplasms
 
 

Download Options